Eterna Therapeutics replaces CEO/president

21 December 2023

Cambridge, USA-based mRNA cell engineering focused biotech Eterna Therapeutics (Nasdaq: ERNA) has appointed Sanjeev Luther as president and chief executive and a member of the company's board of directors, effective January 1, 2024.

Mr Luther will replace Matt Angel, Eterna’s current president and CEO.

Eterna chairman James Bristol commented: “We are excited to have Sanjeev take on the role of president and CEO of Eterna as we continue our work to support the development of next-generation therapies using mRNA cell engineering. Sanjeev has an impressive track record in leadership, strategic planning, and business development across various global organizations in the pharmaceutical and healthcare sectors. The board looks forward to working with Sanjeev as Eterna continues to capitalize on its in-licensed portfolio of patented mRNA cell engineering technologies.”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK